Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
- PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023.
- 05/08/2023
|
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
- Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
- 03/21/2023
|
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
- TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
- 02/09/2023
|
Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
- PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Chairman and Chief Executive Officer Al Altomari will present a corporate overview at the conference on Monday, December 5 at 3:20 p.m. ET.
- 12/01/2022
|
Agile Therapeutics, Inc. (AGRX) Q3 2022 Earnings Call Transcript
- Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief Executive Officer Amy Welsh - Chief Commercial Officer Jason Butch - Chief Accounting Officer Conference Call Participants Oren Livnat - H.C. Wainwright Nazibur Rahman - Maxim Group LLC Operator Good afternoon, and welcome to the Agile Therapeutics Third Quarter 2022 Financial Results Conference Call.
- 11/07/2022
|
Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
- Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
- 10/26/2022
|
Agile Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- PRINCETON, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Chairman and Chief Executive Officer Al Altomari and Vice President of Marketing Amy Welsh will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York, NY. Details on the Company presentation are as follows:
- 09/06/2022
|
These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
- Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
- 09/02/2022
|
Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q2 2022 Results - Earnings Call Transcript
- Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman and CEO Amy Welsh - VP, Marketing Conference Call Participants Oren Livnat - H.C. Wainright Operator Good afternoon, and welcome to the Agile Therapeutics Second Quarter 2022 Financial Results Conference Call.
- 08/11/2022
|
Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
- Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
- 07/28/2022
|
Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch
- More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/11/2022
|
What to Know About Buying Penny Stocks on July 7th
- Here's what you need to know about trading penny stocks on July 6th The post What to Know About Buying Penny Stocks on July 7th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/07/2022
|
Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving
- Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/27/2022
|
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
- PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL. Details on the Company presentation are as follows:
- 05/17/2022
|
Agile Therapeutics, Inc. (AGRX) CEO Al Altomari on Q1 2022 Results - Earnings Call Transcript
- Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q1 2022 Results Conference Call May 12, 2022 4:30 PM ET Company Participants Matt Riley - Head, IR Al Altomari - Chairman, CEO Dennis Reilly - CFO Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good afternoon, and welcome to the Agile Therapeutics' First Quarter 2022 Financial Results Conference Call.
- 05/12/2022
|
Agile Therapeutics (AGRX) Stock: 1-For-40 Reverse Stock Split Goes Into Effect
- A 1-for-40 reverse stock split of Agile Therapeutics, Inc. (Nasdaq: AGRX) has gone into effect. These are the details.
- 04/27/2022
|
Hot Penny Stocks to Buy Today? 3 For Your Watchlist
- Here's what you need to know about trading penny stocks on April 26th The post Hot Penny Stocks to Buy Today? 3 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/26/2022
|
Best Penny Stocks Today? 4 To Buy For Under $1 According To Reddit
- Popular Reddit penny stocks to watch under $1. The post Best Penny Stocks Today?
- 04/18/2022
|
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes
- Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/13/2022
|
Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today
- Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/12/2022
|
Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
- Agile Therapeutics has finished its first full year as a commercial company and was able to establish an attractive growth curve for Twirla in several metrics.
- 04/04/2022
|
Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q4 2021 Results - Earnings Call Transcript
- Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q4 2021 Results - Earnings Call Transcript
- 03/30/2022
|
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
- Agile Therapeutics (AGRX) delivered earnings and revenue surprises of -17.65% and 3.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/30/2022
|
Agile Therapeutics to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Wednesday, March 30, 2022
- Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
- 03/07/2022
|
Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
- PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 7:30 a.m. ET.
- 01/05/2022
|
Agile Therapeutics to Present at the Biotech Showcase and H.C. Wainwright BioConnect Virtual Conferences
- PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022.
- 01/05/2022
|
Top Penny Stocks For Your Under $1 List Right Now
- Check these Under $1 penny stocks out for your watchlist The post Top Penny Stocks For Your Under $1 List Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/01/2021
|
Agile Therapeutics: Worst Is Over
- After trading down from $2.86/share to $.75/share so far this year, Agile's share price is reflecting worse-case scenario. Despite the market sell-off, Agile's business is actually ramping up.
- 11/13/2021
|
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2021 Results - Earnings Call Transcript
- Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2021 Results - Earnings Call Transcript
- 11/02/2021
|
Agile Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on Tuesday, November 2, 2021
- Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
- 10/22/2021
|
Agile Therapeutics: Bullish On Capitulation And Max Pain
- Agile Therapeutics: Bullish On Capitulation And Max Pain
- 10/19/2021
|
Top Penny Stocks to Watch Making Big Moves Right Now
- If you're making a penny stocks watchlist right now, check these three small-caps out The post Top Penny Stocks to Watch Making Big Moves Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/19/2021
|
AGRX Stock: Why It Fell This Past Week
- The stock price of Agile Therapeutics Inc (NASDAQ: AGRX) fell over 20% this past week. This is why it happened.
- 10/13/2021
|
Best Biotech Penny Stocks on Reddit to Buy Now? 4 For Your Watchlist
- Looking for biotech penny stocks to watch on Reddit? Check these four out for your list The post Best Biotech Penny Stocks on Reddit to Buy Now?
- 10/12/2021
|
Agile Therapeutics Applauds Congressional Chairs' Letter to Biden Administration Requesting Enforcement of Contraceptive Access Under Affordable Care Act
- PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today applauded House Congressional Committee leaders in urging the Secretaries of U.S. Departments of Health and Human Services (HHS), Treasury, and Labor to enforce the law regarding women's access to contraceptive methods as dictated by the Affordable Care Act (ACA).
- 10/12/2021
|
Agile Therapeutics Appoints Josephine Torrente to its Board of Directors
- PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Josephine Torrente has been appointed to the Company's board of directors, as a Class II director, effective as of October 7, 2021. Ms. Torrente will serve on Agile's Science and Technology Committee and Nominating and Corporate Governance Committee.
- 10/08/2021
|
Agile Therapeutics Announces Pricing of $22,666,650 Underwritten Public Offering of Common Stock and Warrants
- PRINCETON, N.J., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the pricing of its underwritten public offering of 26,666,648 shares of its common stock and warrants to purchase 13,333,324 shares of its common stock at a combined offering price to the public of $0.85 per one share of common stock and one-half of a warrant to purchase one share of common stock. The warrants have an exercise price of $0.85 per share of common stock, are exercisable immediately, and will expire five years from the date of issuance. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $22,666,650. All securities in the offering will be sold by Agile Therapeutics.
- 10/08/2021
|
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Warrants
- PRINCETON, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 10/07/2021
|
Agile Therapeutics Announces Addition of Twirla® to a Preferred Drug Position on Medi-Cal Formulary
- Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021 Largest Medicaid program in the U.S. adds Twirla to Preferred Drug List as of October 1, 2021
- 10/04/2021
|
Agile Therapeutics to Participate in Upcoming Investor Conferences
- PRINCETON, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the following virtual investor conferences during the month of September 2021.
- 09/07/2021
|
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women's Access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system
- PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth service, which will establish the first telehealth relationship for Agile and offer an additional point of access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system in a fast-growing channel.
- 08/20/2021
|
Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy
- Agile Therapeutics recently reported their Q2 earnings with a beat on EPS and a miss on revenue. The company's flagship product, Twirla, is already starting to display impressive growth trends. The market had a difficult time determining which direction it wants to take the share price, which has provided me an opportunity to add to my AGRX position.
- 07/30/2021
|
2 Penny Stocks Insiders Are Buying
- When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
- 07/30/2021
|
3 Penny Stocks Insiders Are Buying
- When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
- 07/29/2021
|
Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q2 2021 Results - Earnings Call Transcript
- Agile Therapeutics, Inc.'s (AGRX) CEO Al Altomari on Q2 2021 Results - Earnings Call Transcript
- 07/26/2021
|
Agile Therapeutics: Q2 Earnings Insights
- Shares of Agile Therapeutics (NASDAQ:AGRX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 66.67% year over year to ($0.20), which beat the estimate of ($0.21).
- 07/26/2021
|
Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021
- Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT
- 07/01/2021
|
Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference
- PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the company will be participating virtually in the William Blair 41st Annual Growth Stock Conference.
- 05/26/2021
|
Agile Therapeutics: Returning To Bullish Outlook After Encouraging Q1 Earnings
- Agile Therapeutics: Returning To Bullish Outlook After Encouraging Q1 Earnings
- 05/08/2021
|
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2021 Results - Earnings Call Transcript
- Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2021 Results - Earnings Call Transcript
- 05/04/2021
|
Agile Therapeutics (AGRX) Reports Q1 Loss, Lags Revenue Estimates
- Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 9.09% and -82.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2021
|
Recap: Agile Therapeutics Q1 Earnings
- Shares of Agile Therapeutics (NASDAQ:AGRX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 100.00% year over year to ($0.20), which beat the estimate of ($0.21).
- 05/04/2021
|
Agile Therapeutics Reports First Quarter 2021 Financial Results
- Prescription Growth Reflects Increasing Demand for Twirla
- 05/04/2021
|
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
- PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system in women with BMI < 25 kg/m2 and women with BMI 25-30 kg/m2 will be presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting from April 30 – May 2.
- 04/30/2021
|
CORRECTING AND REPLACING -- Agile Therapeutics
- PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2021" instead of "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020". The corrected release follows:
- 04/20/2021
|
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
- Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT
- 04/20/2021
|
7 Beaten Down Stocks with Significant Insider Buying
- Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.
- 04/09/2021
|
Agile Therapeutics to Present at Upcoming March Investor Conferences
- PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at two investor conferences in March.
- 03/05/2021
|
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q4 2020 Results - Earnings Call Transcript
- Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
- Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors
- Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available
- 03/01/2021
|
Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021
- Live Conference Call and Webcast at 4:30 p.m. ET
- 02/19/2021
|
What's Happening At Agile
- What's Happening At Agile
- 02/16/2021
|
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
- PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.
- 01/04/2021
|
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
- PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on Thursday, January 14, 2021, at 9:10 a.m. ET.
- 12/21/2020
|
Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch
- Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA approved product is not easy and has plenty of unknowns. I point out some things to keep an eye out for before and after Twirla's launch.
- 12/07/2020
|
Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch
- Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)
- 12/07/2020
|
Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception
- PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results from the Phase 3 SECURE study evaluating Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. The results have been published online in Contraception (https://bit.ly/SECUREStudy) and will also appear in a future print edition of the journal.
- 11/30/2020
|
Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
- PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat at the Piper Sandler 32nd Annual Healthcare Conference, being held December 1-3, 2020.
- 11/23/2020
|
Agile Therapeutics' Q3 Focused on Launching Its New Contraceptive Patch
- The drugmaker will soon give Twirla a twirl.
- 11/13/2020
|
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2020 Results - Earnings Call Transcript
- Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2020 Results - Earnings Call Transcript
- 11/12/2020
|
Agile Therapeutics Reports Third Quarter 2020 Financial Results
- Commercial Launch of Twirla® Expected by Year-End 2020
- 11/12/2020
|
Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020
- Live Conference Call and Webcast at 4:30 p.m. ET
- 11/04/2020
|
Redding Hero Carries A Chainsaw, And Works In Emergency Response
- We all know someone who's making a difference. Let's help share their amazing stories! Presented by Ring.
- 10/09/2020
|
Storms Knock Down Trees; COVID-19 Church Outbreak | NH Right Now
- Plus: Local Heroes; fatal motorcycle crash; pumpkin patch, pie, and trick-or-treating; truck crashes into garage; breaking news.
- 10/08/2020
|
Global Intrauterine Contraceptive Devices Market Product Spectrum Elaboration, Volume and Revenue| Bayer Healthcare AG, Teva Pharmaceutical Industries Ltd, Actavis PLC
- Sep 30, 2020 (WiredRelease via Comtex) --
The latest research report provides a complete assessment of the Global Intrauterine Contraceptive Devices market...
- 09/30/2020
|
Wisconsin Heroes: Tell Us Who's Made A Difference In Your Life!
- The helpers are the people who make life better. Nominate your Local Heroes to give them the recognition they deserve, presented by Ring.
- 09/11/2020
|
Agile Therapeutics: Taking A Victory Lap While We Wait For Twirla's Commercial Launch
- My original Agile Therapeutics investment thesis and plan have worked out exactly how I planned them. Now, I am looking to take a victory lap ahead of Twirla's commercial launch.
- 08/31/2020
|
Employee Says Sign Restrictions May Impact Palatine Businesses
- An employee at a Palatine business voiced his concern over the impact of sign restrictions put in place by the village during the pandemic.
- 08/28/2020
|
How to build a spud tower: an edible treasure hunt with a guaranteed bounty
- It doesn’t take much effort to grow your own potatoes, and across most of Australia, now is the perfect time to plant them
- 08/24/2020
|
Agile Therapeutics Strengthens Executive Leadership Team with the Appointment of Paul Korner, MD, MBA, as Chief Medical Officer
- PRINCETON, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD, MBA, to the position of Chief Medical Officer. Dr. Korner is a board-certified obstetrician and gynecologist with more than 20 years of pharmaceutical and biotech industry experience, including significant experience within women’s healthcare. He will be responsible for supporting the commercial launch of Twirla®, advancing the Company’s internal pipeline and evaluating external growth opportunities. Dr. Korner will report to Al Altomari, Agile’s Chairman and Chief Executive Officer. "We are excited to welcome Dr. Korner to Agile as we continue to strengthen and expand our senior leadership team," said Al Altomari. "Dr. Korner’s private practice work and his deep pharmaceutical experience, particularly in leading multiple women’s health product approvals and launches, makes him a natural fit as we continue to advance Twirla towards commercial launch and broaden our women’s health portfolio for areas of unmet need."Dr. Korner has served in various leadership positions of increasing responsibility at several global companies focused on female reproductive health, including Solvay Pharmaceuticals, Wyeth Research, Bayer, and Ferring Pharmaceuticals. Dr. Korner has led more than 50 clinical trials that include multiple engagements with the U.S. Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency in Japan, and Health Canada. Most recently Dr. Korner brought his clinical and development acumen to the gene therapy space as a Senior Vice President of Clinical Development & Medical Affairs at Axovant Gene Therapies, Ltd."Agile is at the forefront of expanding healthcare options for women, and I am thrilled to join the Company at this important time. I look forward to supporting Agile’s continued product development and the launch of Twirla, an innovative and important new contraceptive option for women,” said Dr. Korner.Dr. Korner received his MD from the Stritch School of Medicine at Loyola University. He also holds an MBA from the Michael J. Coles College of Business at Kennesaw State University. He currently serves on the Laidlaw Venture Partners Scientific Advisory Board and the Board of Directors of Voltron Therapeutics as an Independent Director.About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.Follow Agile on LinkedIn and Twitter: @AgileTher.Contact: Matt Riley Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com
- 08/17/2020
|
Agile Therapeutics to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
- PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a panel discussion as part of Maxim Group’s M-Vest Virtual Conference Series: Leading Innovators in Women’s Health, beginning at 10:00 a.m. Eastern Time on Thursday, August 13, 2020. The panel will be moderated by Jason McCarthy, PhD, lead biotechnology analyst at Maxim Group. Webcast Details: * Date and Time: Thursday, August 13, 10:00 a.m. Eastern time * Registration Link: https://bit.ly/2DlgeRWAbout Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.Follow Agile on LinkedIn and Twitter: @AgileTher.Contact: Matt Riley Head of Investor Relations mriley@agiletherapeutics.com
- 08/11/2020
|
Agile Therapeutics Reports Second Quarter 2020 Financial Results
- Twirla® on Track for Commercial Launch in Fourth Quarter 2020 $87.2 Million in Cash and Cash Equivalents as of June 30, 2020 Management to Host Conference Call at 4:30 PM ETPRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and six months ended June 30, 2020 and provided a corporate update.“Thanks to the dedication and commitment of the Agile team, we made considerable progress on our objectives and we believe we are on track to launch Twirla in the fourth quarter of 2020. During the second quarter, we transitioned into the final validation phase of manufacturing commercial product. Through Syneos Selling Solutions, our contract sales force partner, we also hired several industry veterans to build out our sales force highlighted by Terry Herring, a recognized leader with more than 30 years of pharmaceutical and healthcare experience, as our new National Sales Leader. We believe our strong financial position and cash balance, combined with our recent achievements, set us up well to commercially launch Twirla and establish Agile in the contraceptive prescription marketplace,” said Al Altomari, Chairman and Chief Executive Officer of Agile.Second Quarter 2020 and Other Recent Corporate Developments:COVID-19 Update * As of today, despite the COVID-19 pandemic, the Company has been able to continue to execute its plans according to planned timelines, including its hiring a sales team, pre-validation and validation of the commercial manufacturing process and its current expectations to ship Twirla to wholesalers. This expectation is subject to change depending on the length, uncertainty or change in market conditions related to the pandemic.Twirla Commercialization Update * In the second quarter 2020, the Company completed production of the planned pre-validation batch of Twirla and transitioned to manufacturing validation batches. * Presently manufacturing three validation batches that the Company expects will produce commercially-usable product. * The Company continues to work with managed care and patient payors to gain market access for Twirla. * Through Syneos Selling Solutions, the Company’s contract sales force partner, hired a national sales leader and seven experienced regional sales managers, and is in the process of hiring a target of 73 total territory and telemarketing sales reps. * The Company intends to begin shipping product to wholesalers in the fourth quarter of 2020.Inclusion into the Russell 3000® and 2000® Indexes * In June 2020, the Company was added to the Russell 3000 and 2000 Indexes, as part of the Russell Indexes annual reconstitution.Financial Guidance * The Company reaffirmed its operating expense guidance for the full year 2020 to be in the range of $52 million to $56 million, with general and administrative expenses accounting for approximately 70% of the spending as it builds out its commercial infrastructure. The Company’s operating expenses guidance includes $2.5 million to $3 million of non-cash stock compensation expense. The Company updated its net revenue guidance in the fourth quarter of 2020, reflecting refined expectations of initial stocking levels, to be in the range of $1 million to $2 million. * Based on the Company’s current business plan and ability to launch Twirla, the Company believes that its cash, cash equivalents and marketable securities as of June 30, 2020 will be sufficient to meet its projected operating requirements through the end of 2021. If the COVID-19 pandemic or other factors impact the Company’s current business plans or its ability to generate revenue from the launch of Twirla, the Company believes it has the ability to revise its commercial plans, including curtailing sales and marketing spending, to allow it to continue to fund its operations.Second Quarter Financial Results * Cash, cash equivalents and marketable securities: As of June 30, 2020, Agile had $87.2 million of cash, cash equivalents and marketable securities compared to $34.5 million of cash and cash equivalents as of December 31, 2019. * Research and development (R&D) expenses: R&D expenses were $3.7 million for the quarter ended June 30, 2020, compared to $1.8 million for the comparable period in 2019. The increase in R&D expenses was primarily due to costs to complete manufacturing development, process improvements, and pre-validation work for commercial manufacturing of Twirla by Corium, the Company’s contract manufacturer. * General and administrative (G&A) expenses: G&A expenses were $6.4 million for the quarter ended June 30, 2020, compared to $1.8 million for the comparable period in 2019. The increase in G&A expenses was primarily due to higher costs associated with our pre-commercialization activities for Twirla, such as brand building, advocacy, market research and consulting. The increase in G&A expenses was also attributable to activities related to building out the commercial organization and included higher salaries and higher professional fees related to recruiting fees and consultants, and an increase in stock compensation expense. * Net loss: Net loss was $10.8 million, or $0.12 per share, for the quarter ended June 30, 2020, compared to a net loss of $3.5 million, or $0.08 per share, for the comparable period in 2019. * Shares Outstanding: At June 30, 2020, Agile had 87,297,605 shares of common stock outstanding.Conference Call and Webcast Agile Therapeutics will host a conference call and webcast to discuss financial results for the second quarter ended June 30, 2020 today at 4:30pm ET. Investors interested in listening to the conference call may do so by dialing (877) 407-2991 for domestic callers or (201) 389-0925 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the Company's website.About Twirla®Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Twirla is indicated for use as a method of contraception by women of reproductive potential with a body mass index (BMI) < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate to prevent pregnancy. Healthcare providers (HCPs) are encouraged to consider Twirla’s reduced efficacy in women with a BMI ≥ 25 to <30 kg/m2 before prescribing. Twirla is contraindicated in women with a BMI ≥ 30 kg/m2. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.About Agile Therapeutics, Inc. Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.Forward-Looking Statement Certain information contained in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the market availability of Twirla, our projected cash position, our projected fiscal year 2020 operating expenses and net revenue and the expected timing and structure of our commercialization plan for Twirla. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties.
- 08/11/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Agile Therapeutics to Host Second Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, August 11, 2020
- Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., July 21, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company,.
- 07/21/2020
|
C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
- C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
- 07/15/2020
|
Hedge Funds Have Never Been This Bullish On Agile Therapeutics Inc (AGRX)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/29/2020
|
How Agile Therapeutics (AGRX) Stock Stands Out in a Strong Industry
- Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 06/23/2020
|
BioMarin's Hemophilia Data, And Other News: The Good, Bad And Ugly Of Biopharma
|
Agile Therapeutics to Join Russell 3000® and 2000® Indexes
- PRINCETON, N.J., June 16, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® and.
- 06/16/2020
|
Billionaire Israel Englander Bets on These 3 Penny Stocks
- Of all the controversial plays on Wall Street, penny stocks take the cake. The risk-tolerant flock to these names as the potential for share prices to grow from pocket change to more than a few dollars is too tempting to ignore.That said, these tickers aren’t without their pitfalls. Some investors avoid them entirely, arguing that the bargain price tags are too good to be true. Rather, the fact that shares are trading at such low levels could reflect problems lying beneath the surface, whether it be poor fundamentals or overpowering headwinds. So, how are investors supposed to distinguish between the long-term winners and those set to come up short? One strategy is to follow the activity of the pros.Enter Israel “Izzy” Englander, who is widely known for his impressive stock picking abilities. Englander expressed interest in the stock market since he was young, and in 1989, co-founded hedge fund Millennium Management with Ronald Shear. Using a broad range of strategies involving a variety of predominantly liquid asset classes, Englander was able to take the $35 million the fund was started with and turn it into $43.49 billion in assets as of June 1, 2020. With an estimated net worth of $6.6 billion in 2020, it’s no wonder Wall Street focus locks in on the guru when he makes a move.Looking to Englander for inspiration, we ran three penny stocks the hedge fund manager snapped up recently through TipRanks’ database to get the analyst community’s take on them. It turns out that each has received Buy ratings from analysts and boasts huge upside potential.Precigen, Inc. (PGEN)Focused on advancing the next generation of gene and cell therapies, Precigen uses precision technology to target urgent and intractable diseases, with its primary therapeutic areas being immuno-oncology, autoimmune disorders and infectious diseases. Given its $3.49 share price, some believe that now is the ideal time to get on board.Among PGEN’s fans are Englander and Millennium. The fund recently pulled the trigger on the stock for the first time, buying up 997,181 shares. As for the value of this new position, it comes in at $3,390,000.JMP analyst Jason Butler is also taking a bullish approach. The analyst wrote in a recent note to clients that key clinical data readouts are coming up in the second half of 2020. Looking at the trials for both PRGN-3005 in ovarian cancer and PRGN-3006 in AML and MDS, they are progressing right on schedule.“Importantly, both programs maintain 100% manufacturing success rate (point-of-care, overnight manufacturing). We believe further confidence in the robustness of the manufacturing process can be inferred from FDA’s decision to now allow the lymphodepletion and non-lymphodepletion arms to enroll concurrently,” Butler commented.Additionally, the company announced that the FDA accepted the Investigational New Drug application for its PRGN-2009 candidate, an immunotherapy for HPV+ cancer. Using PGEN’s AdenoVerse platform as well as a gorilla adenoviral vector, repeat dosing is possible, and the Phase 1/2 trial is set to kick off this calendar year. With preclinical models showing monotherapy activity with PRGN-2009 and enhanced activity with combinations that could target tumors non-responsive to checkpoint inhibitors, Butler is optimistic that the candidate will be effective.If that wasn’t enough, interim results from ActoBiotics’ AG019 in Type 1 diabetes and top line Phase 1 results for INXN-4001 in heart failure are slated for release in 2H20. Combine additional cost reductions at its MBP Titan subsidiary, sufficient cash to fund the company well into 2021 and no impacts from COVID-19, and you get a thumbs up from Butler.To this end, Butler rates PGEN an Outperform (i.e. Buy) along with a $13 price target. This target conveys his confidence in PGEN’s ability to soar 272% in the next year. (To watch Butler’s track record, click here) Turning now to the rest of the Street, it has been relatively quiet when it comes to other analyst activity. Only one other rating was issued recently, but it was also bullish. With a $9 average price target, the upside potential lands at 158%. (See PGEN stock analysis on TipRanks)BiomX (PHGE)Developing bacteriophage-based therapies, BiomX targets bacteria that affect the appearance of skin, as well as chronic diseases like inflammatory bowel diseases, primary sclerosing cholangitis and cancer. Currently going for $4.71 apiece, its share price could present a unique buying opportunity.Englander didn’t miss out on the chance to get in on the action. Adding a new PHGE position to the fund in Q1, Millennium snapped up 150,961 shares, with the holding valued at $1,057,000.Weighing in on BiomX's growth prospects for Cantor, analyst Kristen Kluska acknowledges that due to COVID-19, there are new timelines for the company's clinical trials. Initial BX002 Phase 1 data (IBD) is now expected in Q4 2020, with Phase 2 data for BX001 (acne) coming in Q2 2021.BiomX recently provided more detail regarding the design of the IBD trials. The initial first in human PK Phase 1a trial will look at 24 patients over two cohorts (BX002 with and without proton pump inhibitors - PPI) and placebo, with the endpoints focusing on the detection of viable phage in stool and the effect of PPI. Going forward, Kluska believes this data readout could potentially drive upside for PHGE.Looking at the Phase 1 results for BX001 in acne that were published in March, the candidate was able to generate a larger reduction in C. acnes for patients with high sebum baseline levels compared to the placebo. Kluska notes that BiomX has incorporated these findings into the Phase 2 trial, and should the therapy produce 10-20% more reductions in lesions than the placebo, it would be a major positive. She added, “Thus, we view this as a significant catalyst for BiomX shares, as results could trigger the global cosmetic company moving forward toward a commercialization plan.”The good news doesn’t end there. “Additional work is being studied with CRC, and the next goal by 1Q21 is to see whether the company can synergistically use phage with a payload with checkpoint inhibitors in mouse models of cancer. In light of many recent pharmaceutical partnerships with microbiome companies, the team sees other areas where XMarker could be used in disease diagnosis or companion diagnostics, which might include IBD, liver disease, NASH, and skin indications,” Kluska stated.With BiomX boasting two-plus years of cash on hand, the deal is sealed for Kluska. As a result, the analyst reiterated an Overweight (i.e. Buy) rating and $19 price target. Should the target be met, a twelve-month gain of 303% could be in store. (To watch Kluska’s track record, click here) BiomX has slipped under most analysts’ radar; the stock’s Moderate Buy consensus is based on just two recent ratings. The average price target stands tall at $8.13, which suggests room for almost 400% upside. (See BiomX stock analysis on TipRanks)Agile Therapeutics (AGRX)Last but not least we have Agile Therapeutics, which focuses on addressing the unmet health needs of women. With one already approved product, Twirla, that provides women with a contraceptive option that doesn’t require taking a daily pill or committing to a longer-lasting method, several members of the Street believe its $2.80 share price looks like a steal.Standing squarely in the bull camp, Englander just upped the ante. Boosting its AGRX position by a whopping 1,204%, Millennium purchased an additional 1,281,855 shares. This move brought the total size of the holding to 1,388,336 shares, with the value landing at $2,582,000.Covering the stock for Oppenheimer, 5-star analyst Leland Gershell points out that during the COVID-19 storm, AGRX hasn’t been sitting idly by. While the onset of the pandemic extended the pre-launch period for Twirla, with the actual launch expected in Q4 2020, this isn’t necessarily a bad thing.“Extended pre-launch window of time appears to be to AGRX's benefit, allowing the company to curate sales professionals who bring skill sets well-adapted to both in-person communication as well as virtual engagement. Initial launch strategy to geographically align with areas most favorable to patient access,” Gershell explained. In addition, the company recently contracted for sales personnel and services with Syneos and inVentiv.Twirla's pre-validation batch has already been completed, with commercial batch manufacturing set to kick off in the next few months, and thus, the company has been laying the groundwork for coverage and reimbursement. “While still early for managed care agreements to be executed, discussions are progressing... Despite patch category to be shared w/MYL's Xulane, we see Twirla's advantages (most importantly, low hormonal dose) as favorable to coverage prospects as well as prescriber/patient choice,” Gershell stated.Speaking to its commercialization plan, Gershell is especially interested to see if AGRX will offer a patch replacement program. This would provide women with the ability to remain protected without the inconvenience of needing to obtain another prescription if a patch is lost, unlike the case with Xulane.To sum it all up, Gershell said, “With an approved product that we project will achieve 2024E sales of ~$340 million, an enterprise value of just ~$210 million, and cash runway through 2021, we view AGRX as attractive.”Based on all of the above, it’s no wonder Gershell reiterated his Outperform call. With an $8 price target, shares could climb 186% higher in the next twelve months. (To watch Gershell’s track record, click here) All in all, other analysts echo Gershell’s sentiment. 4 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Given the $7.50 average price target, the upside potential comes in at 168%.
- 06/10/2020
|
Edited Transcript of AGRX earnings conference call or presentation 5-May-20 8:30pm GMT
- Q1 2020 Agile Therapeutics Inc Earnings Call
- 05/28/2020
|
Perceptive Advisors Llc Buys Iovance Biotherapeutics Inc, Zymeworks Inc, Regeneron ...
|
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2020 Results - Earnings Call Transcript
- Agile Therapeutics, Inc. (NASDAQ:AGRX) Q1 2020 Earnings Conference Call May 05, 2020, 16:30 ET Company Participants Matthew Riley - IR Alfred Altomari - Chairma
- 05/11/2020
|
Agile Therapeutics to Participate in Virtual Fireside Chat as part of the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2020
- PRINCETON, N.J., May 11, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer,.
- 05/11/2020
|
Agile Therapeutics to Participate in Virtual Fireside Chat as part of the —…—… RBC ...
|
17 Healthcare Stocks Moving In Friday's Pre-Market Session
|
Is the Options Market Predicting a Spike in Agile Therapeutics (AGRX) Stock?
- Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
- 05/07/2020
|
66 Biggest Movers From Yesterday
|
20 Healthcare Stocks Moving In Thursday's Pre-Market Session
|
58 Stocks Moving In Wednesday's Mid-Day Session
|
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
- 05/06/2020
|
Agile Therapeutics Q1 EPS $(0.100) Misses $(0.090) Estimate
|
Agile Therapeutics Reports First Quarter 2020 Financial Results
- “At the beginning of the COVID-19 pandemic, we took proactive steps by moving all employees to work from home settings for their health and safety, while pursuing business continuity during this pivotal time in the Company’s history,” said Al Altomari, Chairman and Chief Executive Officer of Agile. With respect to our manufacturing process, we have completed production of the pre-validation batch and subject to final quality control testing that we expect to be completed soon, we will transition into the final validation phase.
- 05/05/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
55 Stocks Moving In Monday's Mid-Day Session
|
Why Agile Therapeutics Stock Is Jumping Today
- What happened Agile Therapeutics (NASDAQ: AGRX), a small-cap women's healthcare company, is starting the week off on the right foot. Specifically, the drugmaker's shares are up by 11.2% on extremely heavy volume, as of 10:40 a.
- 05/04/2020
|
20 Healthcare Stocks Moving In Monday's Pre-Market Session
|
30 Stocks Moving in Monday's Pre-Market Session
|
98 Biggest Movers From Friday
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Agile Therapeutics: Billion Dollar Buy-Out Is On The Horizon
- Agile Therapeutics is currently trading substantially below its fair value of $6.36/shr on a stand-alone basis. Agile's leading drug, Twirla, is much more valua
- 05/01/2020
|
Agile Therapeutics to Host First Quarter 2020 Financial Results and Business Update Conference Call on Tuesday, May 5, 2020
- Agile Therapeutics, Inc. (AGRX), a forward-thinking women’s healthcare company, today announced it will report first quarter 2020 financial results after the market close on Tuesday, May 5, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update. Investors interested in listening to the conference call may do so by dialing (877) 407-2991 for domestic callers or (201) 389-0925 for international callers.
- 04/23/2020
|
Spectrum Pharmaceuticals Appoints Seth H.Z. Fischer to Board of Directors
- Spectrum Pharmaceuticals Appoints Seth H.Z. Fischer to Board of Directors
- 04/23/2020
|
Agile Therapeutics nominates Sharon Barbari to board of directors AGRX;CYTK;GILD
- Agile Therapeutics nominates Sharon Barbari to board of directors AGRX CYTK GILD
- 04/22/2020
|
Agile Therapeutics Announces Changes to its Board of Directors
- Agile Therapeutics, Inc. (AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon Barbari for election as a class III director to replace Abhijeet Lele, a member of the company’s board of directors and the board’s Lead Independent Director, who will
- 04/22/2020
|
Agile Therapeutics (AGRX) Flat As Market Sinks: What You Should Know
- Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.
- 04/01/2020
|
Agile Therapeutics (AGRX) Flat As Market Sinks: What You Should Know
|
Week 14 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
- Two sample Breakout Stocks for Week 14 with better than 10% short-term upside potential. The MDA Breakout portfolio is up +11.10% YTD compared to the S&P 500 -2
- 03/28/2020
|
RBC Capital Keeps a Buy Rating on Agile Therapeutics (AGRX)
- In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Agile Therapeutics (AGRX), with a price target of $8.00. The
- 03/25/2020
|
RBC Capital Keeps a Buy Rating on Agile Therapeutics (AGRX)
- In a report released today,
Randall Stanicky
from RBC Capital reiterated a
Buy
rating on Agile Therapeutics (
AGRX
–
Research Report
), with a price target of
$8.00
. The company’s shares closed last Monday at $1.85.
According to
TipRanks.com
, Stani
- 03/25/2020
|
Analysts Offer Insights on Healthcare Companies: Agile Therapeutics (AGRX) and Vir Biotechnology (VIR)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agile Therapeutics (AGRX) and Vir Biotechnology (VIR) with
- 03/25/2020
|
Analysts Offer Insights on Healthcare Companies: Agile Therapeutics (NASDAQ: AGRX) and Vir Biotechnology (NASDAQ: VIR)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agile Therapeutics (
AGRX
–
Research Report
) and Vir Biotechnology (
VIR
–
Research Report
) with bullish sentiments.
Agile Therapeutics (AGRX)
Oppenheime
- 03/25/2020
|
Agile Therapeutics (AGRX) Stock Remains a Top Pick, Says Analyst
- Over the last month, shares of micro-cap biotech Agile Therapeutics (AGRX) have crashed by an alarming 55%. Following such a remarkable decline, you would think the company must be in real trouble, but not so, says one analyst.Maxim’s Jason McCarthy argues that not only does the pullback set up an “attractive entry point,” if you take a deeper look at the company’s finances and catalysts, there’s a very attractive opportunity at play.Although volatility currently reigns supreme across the board, since the turn of the year, AGRX has been on a unique rollercoaster ride. Less than six weeks ago, Agile’s share price was on the rise following the FDA’s approval of Twirla, the company’s contraceptive patch. As it stands, the plan to launch Twirla in Q4 still remains on track. So far, there have been no delays from manufacturing partner Corium.Additionally, McCarthy notes, after recent measures, Agile has a very healthy balance sheet. In February, Agile secured a loan deal from Perceptive Advisors, for $35 million, which is interest free until 2023. Also last month, Agile raised an additional $48 million from equity financing.McCarthy said, “YE-19 cash was $34.5M. Remember, that alone would have likely gotten the company through 2020. However, when we combine the loan from Perceptive, use of the ATM and the $48M in net proceeds from the 2/21 equity financing, Agile should have ~$100M in cash. With Twirla launching later this year, there should be at least 2 years of runway, possibly longer depending on the launch trajectory.”Based on the combination of an approved drug, a strong balance sheet and favorable timelines to “weather the COVID-19 storm,” the analyst rates Agile as a “top pick in our coverage universe.”Therefore, McCarthy reiterates a Buy rating on Agile along with a $8 price target. The implication for investors? Possible upside of a sky scraping 406%. (To watch McCarthy’s track record, click here)The Street agrees. Agile’s Strong Buy consensus rating breaks down into solely Buy ratings – 5, in fact. The average price target comes in identical to McCarthy’s, at $8.00. (See Agile stock analysis on TipRanks)
- 03/23/2020
|
Agile Therapeutics (AGRX) Stock Remains a Top Pick, Says Analyst
- Over the last month, shares of micro-cap biotech Agile Therapeutics (AGRX) have crashed by an alarming 55%. Following such a remarkable decline, you would
- 03/23/2020
|
Analysts Are Bullish on These Healthcare Stocks: Avid Bioservices (CDMO), Agile Therapeutics (AGRX)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avid Bioservices (CDMO), Agile Therapeutics (AGRX) and
- 03/20/2020
|
H.C. Wainwright Reiterates Buy on Agile Therapeutics, Lowers Price Target to $6
|
Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options
- Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
- 03/18/2020
|
Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options
|
Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.
|
Weekly CFO Buys Highlight
- Recent buys from company CFOs Continue reading...
- 03/15/2020
|
Week 12 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
- Two sample Breakout Stocks for Week 12 with better than 10% short-term upside potential. The MDA Breakout portfolio is up +11.60% YTD compared to the S&P 500 -1
- 03/15/2020
|
Weekly CFO Buys Highlight
|
CCL, EXPE among premarket losers
- ZAGG (NASDAQ:ZAGG) -44% after ending strategic review with no deal and Q4 earnings.Sasol (NYSE:SSL) -37%.Party City Holdco (NYSE:PRTY) -36% on Q4 earnings.Norwegian Cruise Line Holdings (NYSE:NCLH) -3
- 03/12/2020
|
Week 11 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
- Four new Breakout Stocks for Week 11 with better than 10% short-term upside potential. The MDA Breakout portfolio is up +37.51% YTD compared to the S&P 500 -8.0
- 03/09/2020
|
100 Biggest Movers From Friday
|
Agile Therapeutics Shares Spike Over $2.40 Resistance Level; Pre-Market Form 4 Filing From CFO Dennis Reilly Showed Purchase Of 75K Shares
|
7 Cheap Stocks Under $7 With Massive Upside Potential
- Cheap stocks - that is, really cheap stocks that trade for single-digit prices - are among the most divisive stocks on Wall Street.Some investors tend to avoid these names entirely. While nominal prices typically don't matter (there's little difference between a $50 stock and a $500 stock), stocks under $10 are different. They often face some sort of difficulty, such as weak fundamentals or overwhelming headwinds. Also, institutional buyers such as pensions and hedge funds often won't buy stocks that are cheaper than $10, and they really become sparse under the $5 mark. Thus, these companies miss out on the steadiness that accompanies institutional ownership.But other investors love cheap stocks. In many cases, they see opportunity in these often battered shares, and some people simply prefer to buy their stocks in "lots" (typically 100 shares at a time) - something that's a little more difficult to do with the triple- and quadruple-digit crowd.The reality is, low-priced stocks are a mix of high-return opportunity but also high risk. The crazy volatility introduced by the coronavirus outbreak certainly doesn't help. Further complicating things is that many of them are largely ignored by the media, making information difficult to come by. So if you are going to take a moonshot, take a cue from the pros that routinely cover these companies.Here are seven of the best cheap stocks under $7. Using TipRanks' Stock Screener tool, we identified seven low-priced stocks that still have decent Wall Street analyst coverage and extremely bullish sentiment. Note that every one of these stocks still comes with colossal risk. But if you're looking to get aggressive and buy cheap on dips, the pros think each of these can offer some promise. SEE ALSO: 13 Super Small-Cap Stocks to Buy for 2020 and Beyond
- 03/03/2020
|
Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
- Biotech stocks came under selling pressure in February, although the degree of weakness was not as worse as the broader market, thanks to strong upward moves by stocks that are levered to COVID-19 epidemic.The FDA approved three new molecular entities, or NMEs, in February, taking the total number of
- 03/02/2020
|
W, VMW among premarket losers
- Big Lots (NYSE:BIG) -35% on Q4 earnings.Tonix Pharmaceuticals (NASDAQ:TNXP) -23% after pricing stock offering.Celsion (NASDAQ:CLSN) -19% after pricing registered direct offering.Wayfair (NYSE:W) -18%
- 02/28/2020
|
Daily Insider Ratings Round Up 2/25/20
- Tables of the top insider purchases and sales filed with the SEC on 2/25/20, based on dollar value. Dollar values often do not equate with significance when it
- 02/28/2020
|
50 Healthcare Stocks Moving In Friday's Pre-Market Session
|
100 Stocks Moving In Thursday's Mid-Day Session
|
Agile Therapeutics, Inc. (Nasdaq: AGRX) to Ring Nasdaq Stock Market Closing Bell on Wednesday, February 26, 2020
- PRINCETON, N.J., Feb. 25, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq.
- 02/25/2020
|
94 Biggest Movers From Friday
- Gainers
Trans World Entertainment Corporation (NASDAQ: TWMC) shares jumped 50.9% to close at $5.28 on Friday after the company disclosed that its subsidiary etailz entered into a...
- 02/24/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
- Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. Merck ...
- 02/23/2020
|
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
|
Chart Industries management to meet with Lake Street GTLS
- Chart Industries management to meet with Lake Street GTLS
- 02/21/2020
|
Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock
- Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions.
- 02/21/2020
|
The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arcus Biosciences Inc (NYSE: RCUS ) BELLUS Health Inc (NASDAQ: BLU ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Calithera Biosciences Inc (NASDAQ: CALA ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Masimo Corporation (NASDAQ: MASI ) (announced its fourth-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Relmada Therapeutics Inc (NASDAQ: RLMD ) Repro-Med Systems, Inc. (NASDAQ: KRMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced $287.5-million debt offering) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Feb. 13) Scpharmaceuticals Inc (NASDAQ: SCPH ) Soligenix, Inc.
- 02/21/2020
|
33 Stocks Moving in Friday's Pre-Market Session
- Gainers
Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 30% to $10.40 in pre-market trading after the company reported the FDA approval of ANJESO for management of moderate to...
- 02/21/2020
|
8 Stocks To Watch For February 21, 2020
- Some of the stocks that may grab investor focus today are: Wall Street expects Deere & Company (NYSE: DE ) to report quarterly earnings at $1.26 per share on revenue of $6.42 billion before the opening bell. Deere shares slipped 0.1% to $165.60 in after-hours trading. Dropbox Inc (NASDAQ: DBX ) reported stronger-than-expected results for its fourth quarter and disclosed a $600 million buyback program. Dropbox shares jumped 10.8% to $20.73 in the after-hours trading session. Analysts expect Colfax Corp (NYSE: CFX ) to report quarterly earnings at $0.56 per share on revenue of $884.28 million … Full story available on Benzinga.com
- 02/21/2020
|
Agile Therapeutics shares are trading lower after the company priced a 15 million share common stock offering at $3 per share.
|
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
- Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering.
- 02/20/2020
|
Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
- Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company’s Lead Product Candidate, Receives FDA Approval.
- 02/20/2020
|
Agile Therapeutics shares are trading lower after the company announced a proposed underwritten public offering of common stock. No size was disclosed.
|
35 Healthcare Stocks Moving In Tuesday's Pre-Market Session
- Gainers
Stealth BioTherapeutics, Inc. (NASDAQ: MITO) stock increased by 38.4% to $3.10 during Tuesday's pre-market session. According to the most recent rating by H...
- 02/18/2020
|
Agile Could Reach $10/Share After Twirla Approval
- Agile Therapeutics received FDA approval for its Twirla contraceptive patch last week. The FDA approval is as expected with required post-marketing studies; the
- 02/18/2020
|
H.C. Wainwright Maintains Buy on Agile Therapeutics, Raises Price Target to $7
|
The Week Ahead In Biotech: Agile, Baudax Bio, Merck and Esperion Await FDA Decisions
- Biotech stocks were quiet in the week ending Feb. 14 amid some data readouts at a couple of conferences and earnings news flow from smid-cap companies. The following are key biotech catalysts to look forward to for the unfolding week: Conferences 34th German Cancer Conference: Feb 19-22 in Berlin, Germany International Association For The Study of Lung Cancer, or IASLC, 2020 Targeted Therapies of Lung Cancer Meeting: Feb. 19-22 in Santa Monica, California Related Link: 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market PDUFA Dates The FDA will rule on Agile Therapeutics Inc's (NASDAQ: AGR ) hormonal contraceptive patch Twirla by the PDUFA action date of Sunday. After two rejections in the past, Twirla managed to snag a positive Adcom verdict in October 2019. Late Monday, the company said it has negotiated a $35-million loan facility that has increased expectations concerning a positive verdict. The FDA is scheduled to issue its verdict on Merck & Co., Inc.'s (NYSE: MRK ) sBLAs for Keytruda dosing schedule updates.
- 02/16/2020
|
FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin
- Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
- 02/14/2020
|
FDA Approves Agile Therapeutics, Inc.'s Twirla® (levonorgestrel and ethinyl estradiol) ...
|
Mid-Morning Market Update: Markets Open Lower; PepsiCo Tops Q4 Views
- Following the market opening Thursday, the Dow traded down 0.5% to 29403.49 while the NASDAQ fell 0.36% to 9691.30. The S&P also fell, dropping 0.33% to 3,368.18.
Leading and...
- 02/13/2020
|
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: AGRX ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptose Biosciences Inc (NASDAQ: APTO ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Avrobio Inc (NASDAQ: AVRO ) Beam Therapeutics Inc (NASDAQ: BEAM ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) NeoGenomics, Inc. (NASDAQ: NEO ) Novartis AG (NYSE: NVS ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PAVmed Inc (NASDAQ: PAVM ) Penumbra Inc (NYSE: PEN ) Prevail Therapeutics Inc (NASDAQ: PRVL )(reacted to the FDA according Orphan Drug Designation to its experimental gene therapy PR001 for treating Gaucher disease) PTC Therapeutics, Inc (NASDAQ: PTCT ) Repligen Corporation (NASDAQ: RGEN ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc.
- 02/13/2020
|
Agile Therapeutics shares are trading lower, not currently seeing company-specific news. NOTE: Co.'s PDUFA date for Twirla is expected for Feb. 16.
|
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …
- 02/12/2020
|
31 Stocks Moving in Wednesday's Pre-Market Session
|
S, TMUS among premarket gainers
- Sprint (NYSE:S) +74% after judge approves T-Mobile merger.Rexahn Pharmaceuticals (NASDAQ:REXN) +25%.ZK International Group (NASDAQ:ZKIN) +21% on supplying stainless steel pipe and fitting products for
- 02/11/2020
|
Agile Finalizes $35M Term Loan Facility As Twirla PDUFA Date Looms
- Agile Therapeutics Inc (NASDAQ: AGRX) shares are advancing Tuesday after the company announced clinching of a term loan facility. The micro-cap biotech that focuses on women's health said late Monday it has finalized a senior secured term loan credit facility with Perceptive Advisors to provide it funding up to $35 million. The facility will disburse term loans in three tranches.
- 02/11/2020
|
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.
- 02/11/2020
|
Agile Finalizes $35M Term Loan Facility As Twirla PDUFA Date Looms
- Agile Therapeutics Inc (NASDAQ: AGRX) shares are advancing Tuesday after the company announced clinching of a term loan facility.
The micro-cap biotech that focuses on women's...
- 02/11/2020
|
Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors
- Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit facility with Perceptive Advisors to provide Agile with up to $35 million through term loans in three tranches. $5 million was funded today after the satisfaction of customary closing conditions, $15 million will be available if Twirla® is approved by the U.S. Food and Drug Administration (“FDA”), and $15 million will be available upon the achievement of certain revenue milestones.
- 02/10/2020
|
Agile Therapeutics Reports Entered $35M Loan Facility With Perceptive Advisors
|
Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
- Biotech stocks have come under some selling pressure in the new year. However, January did witness some strong stock-specific upward moves, especially with stocks leveraged to the Wuhan coronavirus epidemic. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Epizyme Inc's (NASDAQ: EPZM ) tazemetostat for the treatment of epithelioid sarcoma and Horizon Therapeutics PLC's (NASDAQ: HZNP ) thyroid eye disease drug Tepezza were among the key FDA approvals that came through in January. The following are the key PDUFA dates to watch for in February. Can Third Time Be Charm For Agile? Company: Agile Therapeutics Inc (NASDAQ: AGR ) Type of Application: NDA Candidate: Twirla Indication: hormonal contraceptive patch Date: Feb. 16 Twirla is an experimental, once-weekly combined hormonal contraceptive patch that contains the active ingredients ethinyl estradiol, a type of estrogen, and levonorgestrel, a type of progestin.
- 02/03/2020
|
30 Stocks Moving in Monday's Pre-Market Session
|
The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics Inc (NASDAQ: AGRX ) Aptose Biosciences Inc (NASDAQ: APTO ) Catalent Inc (NYSE: CTLT ) Cabaletta Bio Inc (NASDAQ: CABA )(announced grant of orphan drug designation for its DSG3-CAART for the treatment of pemphigus vulgaris) AtriCure Inc. (NASDAQ: ATRC ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Fate Therapeutics Inc (NASDAQ: FATE ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ )(confirmed it is working on treatment/vaccines for coronavirus) Nevro Corp (NYSE: NVRO ) Profound Medical Corp (NASDAQ: PROF ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA )(reacted to publication of positive data readout for its lead drug candidate) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc. (NYSE: WST ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 29) Avanos Medical Inc (NYSE: AVNS ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc.
- 01/30/2020
|
The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc (NASDAQ: XLRN ) ( announced positive Phase 2 results for its pulmonary hypertension drug) Agile Therapeutics Inc (NASDAQ: AGRX ) AtriCure Inc. (NASDAQ: ATRC ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Catalent Inc (NYSE: CTLT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Profound Medical Corp (NASDAQ: PROF ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) SI-Bone Inc (NASDAQ: SIBN ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB )(H.C. Wainwright reiterated a Buy rating on shares) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 28) Correvio Pharma Corp (NASDAQ: CORV ) Endologix, Inc. (NASDAQ: ELGX ) Galectin Therapeutics Inc. (NASDAQ: GALT ) Heat Biologics Inc (NASDAQ: HTBX ) Neuronetics Inc (NASDAQ: STIM ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Salarius Pharmaceuticals Inc (NASDAQ: SLRX ) X4 Pharmaceuticals Inc (NASDAQ: XFOR ) VIVUS, Inc. (NASDAQ: VVUS ) Stocks In Focus Novartis Q4 Sales, Core Income Rise, Guides to Sales, Earnings Growth Novartis AG (NYSE: NVS ) said its fourth-quarter sales rose 8% to $12.403 million, up 8% year-over-year.
- 01/29/2020
|
70 Biggest Movers From Yesterday
- Gainers
Armata Pharmaceuticals, Inc. (NYSE: ARMP) shares surged 77.1% to close at $4.94 on Tuesday. Armata Pharmaceuticals and Innoviva reported a $25 million strategic...
- 01/29/2020
|
12 Healthcare Stocks Moving In Wednesday's Pre-Market Session
|
Stocks That Hit 52-Week Highs On Tuesday
- During Tuesday's morning trading, 152 companies set new 52-week highs.
Things to Consider:
NantHealth (NASDAQ: NH) was the biggest firm by market cap to hit a new...
- 01/28/2020
|
Agile Therapeutics shares are trading higher. Not seeing any company-specific news to justify the price action.
|
70 Biggest Movers From Friday
- Gainers
NanoViricides Inc (NYSE: NNVC) shares rose 54.5% to close at $8.45 on Friday after gaining 43.2% on Thursday.
SAExploration Holdings Inc (NASDAQ: SAEX) shares jumped 33%...
- 01/27/2020
|
Week 5 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
- Two sample Breakout Stocks for Week 4 with better than 10% short-term upside potential and one sample Dow 30 stock pick. The streak of weekly selections gaining
- 01/25/2020
|
Stocks That Hit 52-Week Highs On Friday
- Before 10 a.m. ET Friday, 350 stocks made new 52-week highs.
Noteables:
The largest company by market cap to hit a new 52-week high was Apple (NASDAQ: AAPL).
The smallest company...
- 01/24/2020
|
44 Stocks Moving In Friday's Mid-Day Session
|
14 Drug Manufacturers—Specialty & Generic Stocks Moving In Thursday's Session
|
Traders Circulate Bullish Blog Post On Agile Therapeutics
|
Micro-Cap Stocks: What They Are & How to Invest in Them
- Over the past year, quite a few micro-cap stocks have delivered enormous returns. Here’s some information about investing in micro-cap stocks, including what have been some of the best micro-cap stocks.
- 01/13/2020
|
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
|
The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 6.) Agile Therapeutics Inc (NASDAQ: AGRX ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) BioNTech SE – ADR (NASDAQ: BNTX ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Inspire Medical Systems Inc (NYSE: INSP ) Nevro Corp (NYSE: NVRO ) Nymox Pharmaceutical Corp (NASDAQ: NYMX ) (announced publication of a peer reviewed research report on the experimental studies for its fexapotide triflutate treatment for prostate enlargement and low-grade prostate cancer) Orthopediatrics Corp (NASDAQ: KIDS ) (announced sale of its adult Vilex business in Tennessee to Squadron Capital and used the proceeds for the repayment of term loan due to Squadron) Oyster Point Pharma Inc (NASDAQ: OYST ) Sanofi SA (NASDAQ: SNY ) (JPMorgan upgraded the shares from Neutral to Overweight, citing an attractive valuation) Soligenix, Inc.
- 01/07/2020
|
The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold
|
Here's How to Play Stocks as US-Iran Tensions Mount
|
65 Biggest Movers From Yesterday
|
42 Stocks Moving In Thursday's Mid-Day Session
|
25 Stocks Moving in Monday's Pre-Market Session
|
33 Stocks Moving In Tuesday's Mid-Day Session
|
Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options
|
28 Healthcare Stocks Moving In Friday's Pre-Market Session
|
38 Healthcare Stocks Moving In Monday's Pre-Market Session
|
Agile Therapeutics shares are trading higher. Not seeing any news to justify the price action. NOTE: The company has rallied approximately 28% over the past 5 trading sessions.
|
Agile Therapeutics shares are trading higher. Not seeing any company-specific news to justify the price action.
|
Daily Insider Ratings Round Up 11/18/19
|
Agile Therapeutics shares are trading higher after Joseph Edelman bought 5.768M shares at an average price of $1.68 per share. When an insider buys shares, the market may perceive it as a sign of confidence in the company's outlook.
|
66 Biggest Movers From Friday
|
41 Stocks Moving In Friday's Mid-Day Session
|
Agile Therapeutics shares are trading lower after the company announced that the FDA extension of the Twiria NDA review period from Nov 16, 2019, to Feb 16, 2020.
|
Agile Therapeutics shares are trading lower after the company announced it would file for a $20 million common stock offering.
|
The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict
|
94 Biggest Movers From Yesterday
|
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
|
